Role of biomarkers in community-acquired pneumonia management  

作　　者：Bahaeddin Onur Hakan BarışDemirbas Arif Gulmez 

机构地区：[1]Department of Emergency Medicine,Istanbul Health and Technology University,Istanbul,Turkey [2]Department of Emergency,PHCC,Al Karaana Health Center,Doha,Qatar [3]Department of Emergency,PHCC,Umm Slala Health Center,Doha,Qatar [4]Department of Family Medicine,PHCC,Al Thumama Health Center,Doha,Qatar

出　　处：《Journal of Acute Disease》2024年第3期87-92,共6页急性病杂志（英文版）

摘　　要：Community-acquired pneumonia(CAP)poses a significant global health threat,particularly affecting vulnerable populations.Biomarkers and scoring systems play a crucial role in diagnosing,assessing severity,and guiding treatment decisions for CAP patients.Biomarkers like C reactive protein,procalcitonin,and the neutrophil-to-lymphocyte ratio aid in diagnosis and severity assessment,while scoring systems such as CURB-65 and Pneumonia Severity Index classify patients into risk categories.Emerging biomarkers(uremia,elevated respiratory rate,hypotension,and age≥65)like serum amyloid A and S100 proteins show promise in predicting disease severity and prognosis.However,further research is needed to determine their precise roles and clinical utility in CAP management.

关 键 词：CURB-65 Community-acquired pneumonia PROCALCITONIN Alpha-1 antitrypsin Serum amyloid A 

分 类 号：R563.1[医药卫生—呼吸系统]